Iohexol vs. diatrizoate. A comparative study in intravenous urography.
A randomized double-blind study comparing the use of iohexol with diatrizoate in intravenous urography was performed in 435 patients in nine centers. Contrast media were evaluated for safety, incidence of adverse side effects, and efficacy. Multiple hematologic and biochemical parameters were observed, as well as blood pressure and pulse, at intervals before and after injection. Severity, nature, and duration of side effects were recorded together with the attending physician's clinical assessment. Coned radiographs of the kidneys were done immediately after injection and were repeated at 1-, 5-, 10-, and 20-minute intervals. Films were evaluated for quality of image. A significantly higher number of excellent studies were obtained with iohexol than with diatrizoate. Remarkably few side effects and adverse reactions reported for iohexol establish the safety and suitability of this nonionic contrast medium for intravenous urography.
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D003287:Contrast Media / Q000633:toxicity*; D003973:Diatrizoate / Q000633:toxicity*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007463:Iodobenzoates / Q000633:toxicity*; D007472:Iohexol; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced; D010292:Paresthesia / Q000139:chemically induced; D011674:Pulse / Q000187:drug effects; D011897:Random Allocation; D014283:Triiodobenzoic Acids / Q000633:toxicity*; D014567:Urography
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D003973:Diatrizoate; D007472:Iohexol